Dear E-druggers,
This is in response to the queries about the status of
drugs: terfenadine, astemizole, guar gum, and temafloxacin.
In relation to temafloxacin, you may ask to FDA " A MedWatch continuing
education article" issue 1996. There appeared a clinical synopsia about this
drug. In this issue the reference number 55: Blumm MD, Graham DJ, McCloskey
CA.Temafloxacin syndrome: a review of 95 cases. Clin Infect Dis 1994;18:946-950.
You could write to Dr. Sthephen Goldman, Associate Director for medicine,
Medwatch, The FDA Medical products Reporting Program, Office of Operations,
HF-2, 5600 Fishers Lane, Room 9-57, Rockville, MD 20857 Fax: (301)
443-5776.
With my best regards,
Arturo Marti-Carvajal
Clinical Epidemiology Unit
Universidad de Carabobo
Venezuela
Fax: 58-41-214092
Postal Address:
FUNDACID
Jet Cargo International
M510
P.O.Box 0200
Miami, Fl 33102-0010
USA
e-mail: amarti@cid.cid.ve
--
Send mail for the `E-Drug' conference to `e-drug@usa.healthnet.org'.
Mail administrative requests to `majordomo@usa.healthnet.org'.
For additional assistance, send mail to: `owner-e-drug@usa.healthnet.org'.